CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Advantages of Using Monoclonal Antibodies

Advantages of Using Monoclonal...

A Brief Overview Of Green Biotechnology Tools And Applications

A Brief Overview Of Green...

Key Advantages of Agtech in Farming

Key Advantages of Agtech in Farming

Nanotechnologys Impact on Environment: What to Know

Nanotechnologys Impact on...

How Automation in Pharmaceutical is Giving a New Direction to Drug Development

How Automation in Pharmaceutical is...

Ways Health Economics and Outcomes Research can Improve Decision Making Process

Ways Health Economics and Outcomes...

Top Agtech Industry Trends to Keep an Eye on

Top Agtech Industry Trends to Keep an...

Strategies to Mitigate Life Sciences Supply Chain Challenges

Strategies to Mitigate Life Sciences...

Advantages of Using Monoclonal Antibodies

Advantages of Using Monoclonal...

A Brief Overview Of Green Biotechnology Tools And Applications

A Brief Overview Of Green...

Key Advantages of Agtech in Farming

Key Advantages of Agtech in Farming

Nanotechnologys Impact on Environment: What to Know

Nanotechnologys Impact on...

How Automation in Pharmaceutical is Giving a New Direction to Drug Development

How Automation in Pharmaceutical is...

Ways Health Economics and Outcomes Research can Improve Decision Making Process

Ways Health Economics and Outcomes...

Top Agtech Industry Trends to Keep an Eye on

Top Agtech Industry Trends to Keep an...

Strategies to Mitigate Life Sciences Supply Chain Challenges

Strategies to Mitigate Life Sciences...

SomaLogic and Illumina to Work on Proteomics and Multi-omics Research

Life Sciences Review Life Sciences Review | Friday, January 21, 2022
Tweet

SomaLogic and Illumina have teamed up to provide customers in the research, clinical, and application markets, unique capabilities from both companies.


Fremont, CA: “This is truly a transformational partnership that will democratize and accelerate our understanding of the human proteome,” comments SomaLogic Chief Executive Officer Roy Smythe, M.D. “It definitively signals that the era of proteomics is here and that SomaLogic, and now Illumina, will lead that era.” SomaLogic, a leader in data-driven proteomics technology, has launched a global strategic partnership with Illumina, the world's leading provider of next-generation sequencing technology. The multi-year deal will bring genomics and proteomics technology platforms together in a major commercial alliance to better enable and empower proteomics and multi-omics research around the world.


The firms will collaborate to produce co-exclusive, co-branded proteomics solutions based on next-generation sequencing (NGS). The two companies will combine Illumina's global commercial infrastructure with SomaLogic's unique proteomics platform, which includes proprietary synthetic aptamer reagents 


 


capable of measuring and identifying 7,000 human proteins, unique bioinformatics tools and capabilities, and the world's largest clinical proteomics database.


For customers in the research, clinical, and applied areas, the cooperation brings together unique strengths from each business. Illumina is a leader in DNA sequencing and array-based technologies around the world. SomaLogic has a 20-year track record of providing highly repeatable measurements of circulating proteins using slow off-rate modified aptamers, known as SOMAmer® reagents, and its patented SomaScan® Platform.


Illumina will develop and implement NGS-based protein identification and measurement tools into laboratories throughout the world, as well as enable the development and usage of high-plex protein pattern recognition tests as part of the deal. SomaLogic was the first to use this method of diagnosis, starting its SomaSignal test program in 2019. The company now offers 12 protein pattern recognition tests created in the lab for a variety of human illnesses and disorders.


Weekly Brief

loading
Towards a New World Order
> <
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue

Read Also

Qualities to Consider when Choosing Life Sciences Business Consultants for Your Firm

How Biotech Startups can Mitigate Risks in Order to Grow Sustainably

Cellf BIO's BioShincter to Undergo Phase 1 Trail to Test Fecal Incontinence Treatment

Fulcrum Therapeutics Announces CEO Transition

An Overview of Wholesalers' Roles in Complex Supply Chains

Veeva Opening Up Integration Module for Future Opportunities and Applications

Veeva Systems To Accelerate the CRM of Life Science Businesses

The Role of Technology in Advancing Clinical Trials

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/somalogic-and-illumina-to-work-on-proteomics-and-multiomics-research-nwid-697.html